| abstract |
The present invention relates generally to immunoconjugates, and more particularly to immunoconjugates comprising a mutant interleukin-2 polypeptide and a bispecific antigen binding molecule that binds PD-1 and Tim-3. In addition, the invention relates to polynucleotide molecules encoding immunoconjugates, as well as vectors and host cells containing such polynucleotide molecules. The invention further relates to methods of producing variant immunoconjugates, pharmaceutical compositions containing the variant immunoconjugates, and uses thereof. [Selection diagram] Figure 1 |